VIENNA — In this exclusive video from the International Liver Congress 2019, James Merson, PhD, global therapeutic area head for infectious diseases at Janssen, discusses the company’s pipeline for hepatitis B with a focus on improving functional cure rates.
“For us at Janssen, HBV and being able to increase functional cure rates of patients living with HBV is an important part of our strategy as to how we can manage the disease more effectively than the current treatments do today,” Merson told Healio Gastroenterology and Liver Disease.
“We have a number of

Source link